Cambridge, UK and New York, US, 24 September 2019. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today … Continue reading “Artios Pharma appoints Tania Dimitrova as Chief Business Officer and expands presence in the United States”
Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today provides a business update for the last twelve months. Following the rebranding of … Continue reading “Neuraxpharm provides business update on a transformational year”
Data to be presented at inaugural STORM Therapeutics RNA Epigenetics in Human Disease Conference in Cambridge, UK 18 September 2019, Cambridge, UK: STORM Therapeutics, the biotechnology company focused on the … Continue reading “STORM Therapeutics presents breakthrough data showing in vivo efficacy and therapeutic proof of concept for targeting RNA modifying enzymes”
Enables development of first-in-class molecular radiotherapy based on PARP inhibitor Offers significant potential for diagnosing and treating a broad range of cancers LONDON, UK, 05 September 2019 – Theragnostics, which … Continue reading “Theragnostics signs agreement with Astrazenenca”
To accelerate development and commercialisation of innovative Glaucoma MIGS device, MINIjectTM WAVRE, Belgium — 5 September 2019: iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the … Continue reading “iSTAR Medical announces EUR 40m Series C Financing”
Los Angeles, September 4, 2019 – ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces that it is scheduled to attend and / or present at the following investor and scientific … Continue reading “ImaginAb to Present at Upcoming Investor and Scientific Conferences in September & October 2019”
Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that it has obtained written feedback from the US Food and Drug Administration (FDA) that will have a significant impact on the ongoing … Continue reading “Positive feedback from FDA significantly benefits ongoing NefIgArd pivotal Phase 3 study”
Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis … Continue reading “Forendo Pharma commences Phase 1b Proof of Mechanism study with its lead endometriosis program, HSD17B1 inhibitor FOR-6219”
20 August 2019, Cambridge, UK: STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapeutics modulating RNA epigenetics, today announced that it will be hosting an … Continue reading “STORM Therapeutics to Host First RNA Epigenetics Conference in Cambridge UK”
Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that it has exclusively in-licensed Budenofalk 3mg oral capsule for the US market from the German pharmaceutical company Dr. Falk Pharma GmbH (“Dr. … Continue reading “Strategic In-Licensing Related to Autoimmune Hepatitis in the US Market”
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces an update on contracts: · Two new biopharmaceutical client contracts with combined value of over £1m · Award of … Continue reading “IXICO Provides an Update on New and Current Contracts”
LONDON, Aug. 05, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data with a … Continue reading “Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD”
Life Sciences industry company operations and communications expert joins the region’s Life Science & Healthcare membership organisation One Nucleus, the Cambridge based not-for-profit membership organisation for the East of … Continue reading “One Nucleus Strengthens Board with Appointment of New Director”
Neuraxpharm launches its first products in the United Kingdom Craig Bowen appointed as General Manager of Neuraxpharm UK -PRESS RELEASE- July 31, 2019 Neuraxpharm Group, a leading European specialty pharmaceutical … Continue reading “Neuraxpharm Launches First Products in the United Kingdom”
Los Angeles, July 24, 2019 – ImaginAb Inc., a clinical-stage immuno-oncology imaging company, announces it has initiated its Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at Dana-Farber Cancer … Continue reading “ImaginAb Initiates Phase II Clinical Trial at a World-Leading Cancer Center”
REPAIR Impact Fund makes two investments after US/Canadian investment round, totaling USD 10 million. The Fund has now invested a total of USD 30 million in six companies. Copenhagen, Denmark, … Continue reading “Novo Holdings REPAIR Impact Fund invests USD 10 million in Curza and Spero”
Sunstone Life Science Ventures joins Forendo Pharma Investor Syndicate Date: July 19, 2019 | author: Forendo Pharma Forendo Pharma, a clinical stage drug development company focusing on novel treatments in … Continue reading “Sunstone Life Science Ventures joins Forendo Pharma Investor Syndicate”
14 July 2019 at 19:00 CET – Gilead to Make $3.95 Billion Upfront Payment and $1.1 Billion Equity Investment – – Gilead Gains Access to Galapagos’ Differentiated Drug Discovery Platform and Current … Continue reading “Gilead and Galapagos Enter Into Transformative Research and Development Collaboration”
Würzburg, Germany – July 11, 2019: vasopharm GmbH, a private biopharmaceutical company developing a novel treatment for traumatic brain injury (TBI), today announced the successful completion of a €9.5 million … Continue reading “vasopharm Closes €9.5 million Financing Round”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2019 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com